Novallia

Portfolio · 1

Nyxoah

Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea

1 round $20.0M committed Latest: 2016-07

Investment activity

1 portfolio exit on record.

Q&A

What is Novallia's primary investment focus by sector?

Novallia primarily focuses on the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.

Can you name a notable exit for Novallia?

Novallia notably exited Nyxoah in September 2020 through a Public Offering event on Euronext, with a valuation of $423M.

Which company is a key part of Novallia's current portfolio?

A key company in Novallia's portfolio is Nyxoah, which develops Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea.

What is Novallia's activity regarding investment stages?

Novallia has participated in at least one B Round investment.

When did Novallia make its most recent recorded investment?

Novallia's most recent recorded investment was in July 2016.

What is the most recent exit event recorded for Novallia?

The most recent exit event for Novallia was in 2020, which was a Public Offering.